TECTONIC THERAPEUTIC, INC. Interest Expense Nonoperating
TECTONIC THERAPEUTIC, INC. (TECX) reported Interest Expense Nonoperating of $6.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Interest Expense
us-gaap:InterestExpenseNonoperating · last filed 2026-08-06
- TECTONIC THERAPEUTIC, INC. interest expense nonoperating for the quarter ending 2026-06-30 was $6.00K, a 64.71% decline year-over-year.
- TECTONIC THERAPEUTIC, INC. interest expense nonoperating for the quarter ending 2026-03-31 was $8.00K, a 60.00% decline year-over-year.
- TECTONIC THERAPEUTIC, INC. interest expense nonoperating for the quarter ending 2025-12-31 was $12.00K, a 45.45% decline year-over-year.
- TECTONIC THERAPEUTIC, INC. interest expense nonoperating for the quarter ending 2025-09-30 was $14.00K, a 44.00% decline year-over-year.
- TECTONIC THERAPEUTIC, INC. interest expense nonoperating for fiscal 2025 was $63.00K, a 41.12% decline from fiscal 2024.
- TECTONIC THERAPEUTIC, INC. interest expense nonoperating for fiscal 2024 was $107.00K, a 29.61% decline from fiscal 2023.
- TECTONIC THERAPEUTIC, INC. interest expense nonoperating for fiscal 2023 was $152.00K.
| Period end | Interest Expense Nonoperating 3 month | Interest Expense Nonoperating 6 month | Interest Expense Nonoperating 9 month | Interest Expense Nonoperating 12 month |
|---|---|---|---|---|
| 2026-06-30 | $6.00K 10-Q · filed 2026-08-06 | $14.00K 10-Q · filed 2026-08-06 | $26.00K derived: sum of 3 quarters · filed 2026-08-06 | $40.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $8.00K 10-Q · filed 2026-05-07 | $20.00K derived: sum of 2 quarters · filed 2026-05-07 | $34.00K derived: sum of 3 quarters · filed 2026-05-07 | $51.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $12.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $26.00K derived: sum of 2 quarters · filed 2026-02-26 | $43.00K derived: sum of 3 quarters · filed 2026-08-06 | $63.00K 10-K · filed 2026-02-26 |
| 2025-09-30 | $14.00K 10-Q · filed 2025-11-06 | $31.00K derived: sum of 2 quarters · filed 2026-08-06 | $51.00K 10-Q · filed 2025-11-06 | $73.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $17.00K 10-Q · filed 2026-08-06 | $37.00K 10-Q · filed 2026-08-06 | $59.00K derived: sum of 3 quarters · filed 2026-08-06 | $84.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $20.00K 10-Q · filed 2026-05-07 | $42.00K derived: sum of 2 quarters · filed 2026-05-07 | $67.00K derived: sum of 3 quarters · filed 2026-05-07 | $95.00K derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $22.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $47.00K derived: sum of 2 quarters · filed 2026-02-26 | $75.00K derived: sum of 3 quarters · filed 2026-02-26 | $107.00K 10-K · filed 2026-02-26 |
| 2024-09-30 | $25.00K 10-Q · filed 2025-11-06 | $53.00K derived: sum of 2 quarters · filed 2025-11-06 | $85.00K 10-Q · filed 2025-11-06 | $118.00K derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $28.00K 10-Q · filed 2025-08-07 | $59.00K 10-Q · filed 2025-08-07 | $93.00K derived: sum of 3 quarters · filed 2025-08-07 | $129.00K derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $31.00K 10-Q · filed 2025-05-08 | $65.00K derived: sum of 2 quarters · filed 2025-05-08 | $101.00K derived: sum of 3 quarters · filed 2025-05-08 | $141.00K derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $34.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $70.00K derived: sum of 2 quarters · filed 2025-03-20 | $110.00K derived: sum of 3 quarters · filed 2025-03-20 | $152.00K 10-K · filed 2025-03-20 |
| 2023-09-30 | $36.00K 10-Q · filed 2024-11-12 | $76.00K derived: sum of 2 quarters · filed 2024-11-12 | $118.00K 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $40.00K 10-Q · filed 2024-08-14 | $82.00K 10-Q · filed 2024-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |